Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
64Cu-benzyl-TETA-MAb 1A3
- Development stage
- Unknown
- Lead developer
- Mallinckrodt Institute of Radiology
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Positron Emitters → Radiopharmaceuticals, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
64Cu-benzyl-TETA-MAb 1A3 is a radiopharmaceutical imaging and therapeutic agent consisting of the monoclonal antibody 1A3 labeled with copper-64, a positron-emitting radionuclide, using the bifunctional chelate benzyl-TETA (bromoacetamidobenzyl-tetraazacyclotetradecane-tetraacetic acid). The monoclonal antibody 1A3 is an anticolorectal carcinoma antibody that specifically targets colorectal cancer cells. Developed at the Washington University School of Medicine and the Mallinckrodt Institute of Radiology, this agent was primarily investigated for PET (positron emission tomography) imaging of colorectal cancer to detect primary and metastatic tumor sites, including small occult lesions. It has also been explored for potential applications in radioimmunotherapy due to the decay properties of copper-64.
- Other names
- 64Cu-labeled MAb 1A364Cu-benzyl-TETA-MAb 1A3
02
Targets
Colorectal carcinoma-associated cell surface antigen recognized by mAb 1A3EPCAM (Epithelial cell adhesion molecule)
Beyond the preview
Go deeper on 64Cu-benzyl-TETA-MAb 1A3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 64Cu-benzyl-TETA-MAb 1A3.